While allosteric mTOR inhibitors such as rapamycin or its analogues have limited efficacy in various cancers in part due to activation of AKT signaling [23–26], second generation mTOR inhibitors can avoid the compensatory activation and elicit deeper inhibition of both mTOR complexes and downstream signaling [13, 27–29]. Here, MTOR is linked to cancer.